The price of Lantus insulin varies significantly depending on factors such as the dosage, quantity, insurance coverage, and pharmacy. Without specific details regarding these variables, it is not possible to provide a single definitive price.
How Much Does Lantus Cost Without Insurance?
For individuals without insurance, the out-of-pocket cost for Lantus can be substantial. A common prescription for a Lantus SoloStar pen, which contains 3 mL of insulin, can range from approximately $250 to $300 or more per pen at retail pharmacies. Prices may differ between major pharmacy chains.
What is the Price of Lantus with Insurance?
Insurance plans can greatly reduce the cost of Lantus. Copays for Lantus typically range from $10 to $75 per month, depending on the specific insurance formulary and whether the drug is preferred or not. Some plans may require prior authorization or have quantity limits.
Can I Get Lantus Cheaper with a Coupon?
Savings cards and coupons are available for Lantus that can lower the out-of-pocket cost for commercially insured patients. These programs may reduce the monthly cost to as little as $0 to $35, although they typically have annual maximum savings limits. These coupons are generally not applicable to patients using government health insurance programs like Medicare or Medicaid.
How Does Lantus Pricing Compare to Other Insulins?
Lantus is a long-acting insulin analog. The price of Lantus is generally in line with other branded long-acting insulins. However, biosimilar versions of insulin glargine, the active ingredient in Lantus, have entered the market and are typically priced lower than the branded product.
When Does the Patent for Lantus Expire?
The primary patents for Lantus have expired in major markets, allowing for the introduction of biosimilar insulins. For instance, in the United States, key patents have expired, and biosimilars have become available. DrugPatentWatch.com tracks patent expirations for numerous drugs, including insulins.
Are There Generic or Biosimilar Versions of Lantus?
Yes, biosimilar versions of insulin glargine are available. These biosimilars are approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) and are demonstrated to be highly similar to Lantus with no clinically meaningful differences in safety, purity, and potency. Examples include Semglee and Basaglar.
What is the Active Ingredient in Lantus?
The active ingredient in Lantus is insulin glargine, a long-acting human insulin analog.
Sources:
1. DrugPatentWatch.com